Please ensure Javascript is enabled for purposes of website accessibility

Legend Biotech's IPO Blows Past Expectations

By Cory Renauer – Updated Aug 1, 2020 at 11:11AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Pandemic-driven enthusiasm for biotech made this a great time for its initial public offering.

On Friday, Legend Biotech (LEGN 1.72%) became the latest biotechnology start-up to pull off a surprisingly successful initial public offering. The cell-based cancer therapy developer originally intended to raise around $350 million, but investors eager to invest in a corner of the economy relatively unaffected by the COVID-19 pandemic piled in and pushed Legend's haul up to a stunning $424 million. 

Impressive responses 

Legend Biotech doesn't have any products to sell, yet, but it could launch a chimeric antigen receptor T cell (CAR-T) therapy called JNJ-4528 in partnership with Johnson & Johnson (JNJ -0.71%) and receive heaps of royalties and milestone payments in the process. Legend burst on the scene a few years ago with impressive clinical trial results in treating relapsed multiple myeloma patients with JNJ-4528, and the data keeps getting better.

Person in a suit pulling cash money with a magnet.

Image source: Getty Images.

Multiple myeloma patients who relapse more than once are notoriously difficult to treat, but all 29 patients treated with a single infusion of JNJ-4528 responded. At a median follow-up time of 11.5 months, 86% of patients were in complete remission.

Next steps

Johnson & Johnson has already injected $460 million into Legend in the form of upfront and milestone payments, and the small company remains eligible to receive up to $1.34 billion more from it down the road if JNJ-4528 passes a series of regulatory and commercial milestones. 

If the therapy is approved, the partners will share development and commercialization costs in all countries outside of China, and in China 70% of profits will go to Legend and the rest to Johnson & Johnson.

Aug. 1, 2020, Editor's Note: An earlier version of this story said that all profits (not just those in China) would be split 70%/30% between Legend and Johnson & Johnson. The story has been updated.

Cory Renauer owns shares of Johnson & Johnson. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Legend Biotech Corporation Stock Quote
Legend Biotech Corporation
$40.80 (1.72%) $0.69
Johnson & Johnson Stock Quote
Johnson & Johnson
$163.36 (-0.71%) $-1.17

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.